AACR 2023: 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
- BCG003 binds to the CRD3 and CRD4 domains of TNFR2 without blocking the binding of TNFα.
- In vitro, BCG003 stimulates the proliferation and activation of hCD8+ T cells, displays ADCC effects on TNFR2–positive cells, and reverses Treg suppression of CD8+ cell proliferation.
- BCG003 monotherapy demonstrates anti-tumor activity and enhances tumor inhibition efficacy in combination with anti-PD-1/PD-L1 antibodies. No toxicity was observed in hTNFR2 mice.
- Nonclinical toxicological pharmacokinetics studies in cynomolgus monkeys are ongoing, and preliminary data suggest good PK and tolerance of BCG003 in cynomolgus monkeys.